Finally, experiments in a xenograft mouse melanoma model highlighted DT2216 potentiating effect of target therapy, not only inducing a significant reduction of tumor growth, but also showing a longer disease control.<h4>Conclusion</h4>Our findings provide new insights for combination therapy including Bcl-xL degradation for melanoma treatment. Here, BCL2L1 is linked to melanoma.